- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: PF-07302048.
Displaying page 1 of 1.
| EudraCT Number: 2020-002641-42 | Sponsor Protocol Number: C4591001 | Start Date*: 2020-09-04 | |||||||||||
| Sponsor Name:BioNTech SE | |||||||||||||
| Full Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COV... | |||||||||||||
| Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005442-42 | Sponsor Protocol Number: C4591007 | Start Date*: 2021-04-28 | |||||||||||
| Sponsor Name:BioNTech SE | |||||||||||||
| Full Title: A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBOCONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A S... | |||||||||||||
| Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005444-35 | Sponsor Protocol Number: C4591015 | Start Date*: 2021-04-15 | |||||||||||
| Sponsor Name:BioNTech SE | |||||||||||||
| Full Title: A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEAL... | |||||||||||||
| Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: In utero, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-005197-25 | Sponsor Protocol Number: C4591031 | Start Date*: 2022-02-22 | |||||||||||
| Sponsor Name:BioNTech SE | |||||||||||||
| Full Title: A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162b2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162b2 | |||||||||||||
| Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001290-23 | Sponsor Protocol Number: C4591024 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:BioNTech SE | |||||||||||||
| Full Title: A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE | |||||||||||||
| Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.